Search clinical trials for: Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)

Total 32 results

Bayer

Completed

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Brain Diseases | Spinal Cord Diseases

United States, Colombia, Argentina, Brazil
Bayer

Completed

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) (GadaCAD 2)

Coronary Artery Disease

United States, Canada, Singapore, Australia
Bayer

Completed

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) (GadaCAD 1)

Coronary Artery Disease

New Zealand, United Kingdom, United States, France, Germany, Korea, Republic of, Switzerland
Bayer

Completed

A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children

Magnetic Resonance Imaging

Sweden, Canada, Austria, Germany
Bayer

Completed

A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting

Contrast Enhancement in Magnetic Resonance Imaging

United States
Bayer

Completed

Drug Use Investigation of Gadovist.

Magnetic Resonance Imaging | Image Enhancement

Japan
Bayer

Completed

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI) (GEMMA 2)

Breast Cancer

Spain, Canada, Taiwan, United States, India, Netherlands, Poland, Germany, Argentina
Bayer

Completed

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

Breast Cancer | Diagnostic Imaging

Italy, Korea, Republic of, Switzerland, Colombia, United States, Brazil, Germany, Finland, Argentina
Bayer

Completed

Myocardial Perfusion MRI

Magnetic Resonance Imaging | Myocardial Perfusion Imaging

Switzerland, Germany, Austria, Poland
Bayer

Completed

Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging

Central Nervous System Diseases

Korea, Republic of, United States, Colombia, China, Argentina
Bayer

Completed

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients

Central Nervous System Diseases

China
Bayer

Completed

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Brain Metastases

Japan
Bayer

Completed

Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging

Central Nervous System Diseases | Diagnostic Imaging

United States, Australia, Germany, Switzerland, Japan, Austria, Colombia, India
Bayer

Completed

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients

Vascular Diseases

China
Bayer

Completed

Gadobutrol Enhanced MRA of the Supra-aortic Vessels (GEMSAV)

Carotid Stenosis

France, China, United States, Austria, Poland, Australia, Italy, Turkey, Germany, Korea, Republic of, Sweden, Switzerland, Czechia, Argentina
Bayer

Completed

GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients (GARDIAN)

Magnetic Resonance Imaging | Magnetic Resonance Angiography

Poland, China, France, Germany, Hungary, Korea, Republic of, South Africa, Spain, Thailand, Taiwan, Czech Republic, Hong Kong, Italy, Kazakhstan, Russian Federation, Bosnia and Herzegovina, Greece, Canada, Vietnam, Kyrgyzstan
Bayer

Completed

Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)

Epidemiologic Factors

Germany
Bayer

Completed

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

Magnetic Resonance Imaging

United States, Canada, Germany
Bayer

Completed

Gadobutrol Enhanced MRA of the Renal Arteries (GRAMS)

Renal Artery Obstruction

Taiwan, United States, Korea, Republic of, France, Turkey, Switzerland, Austria, Poland, Brazil, Colombia, Germany, Czech Republic, Argentina
Bayer

Completed

Safety of Gadovist in Renally Impaired Patients (GRIP)

Fibrosis | Renal Impairment

Italy, Spain, Korea, Republic of, Germany, Canada, France, Austria, Thailand, Australia, Switzerland
Bayer

Completed

Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging

Magnetic Resonance Imaging

Japan
Bayer

Completed

Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging

Magnetic Resonance Imaging

Philippines
Bayer

Completed

Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.

Neoplastic CNS Lesions

Italy
Bayer

Completed

Gadobutrol Magnevist-controlled Body Study

Magnetic Resonance Imaging

China, Korea, Republic of, Japan
Bayer

Completed

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose (LEADER 75)

Magnetic Resonance Imaging

United States, Korea, Republic of, France, Germany, Italy, Switzerland, United Kingdom
University Hospital, Grenoble

Not yet recruiting

Acceleration of the Kinetics of Diffusion of Gadolinium in the Perilymphatic Structures of the Inner Ear. (FAST-HYDROPS)

Inner Ear ; Meniere's Disease; Imaging
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions

Lymphoma | Brain Neoplasm | Metastatic Malignant Neoplasm in the Brain | Recurrent Malignant Brain Neoplasm

United States
Guerbet
Bayer AG (Sponsor); Bracco (Sponsor); GEHC (Sponsor)

Recruiting

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (ODYSSEY)

Cognitive Function | Motor Function | Contrast Media

United States, Korea, Republic of, Italy, Brazil, Canada, Russian Federation, France, Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

Hepatocellular Carcinoma | Liver and Intrahepatic Bile Duct Disorder | Metastatic Malignant Neoplasm in the Liver | Primary Malignant Liver Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer

Stage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Not yet recruiting

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

Prostate Carcinoma

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

Multiple Sclerosis | Metastatic Malignant Neoplasm in the Brain | Adult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Ependymoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult... and other conditions

United States

Search clinical trials for: Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations